Form 4 for NSRX Nasus Pharma Ltd
Accepted 2026-06-22 07:12:42 ET · period of report 2026-06-17 · accession 0001493152-26-029484 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-22 07:12 | 2026-06-17 | NSRX | Teleman Dan Benjamin | CEO, Dir | P - Purchase | $3.10 | +6,550 | 163.5K | +4% | +$20.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-06-17 | P | A | 6,550 | $3.10 | 163,541 | D | — | — | (F1) Consists of: (i) 30,696 ordinary shares, no par value per share ("Ordinary Shares"), and (ii) 132,845 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days. |